CN101965188A - 眼相关疾病的治疗 - Google Patents

眼相关疾病的治疗 Download PDF

Info

Publication number
CN101965188A
CN101965188A CN2009801075816A CN200980107581A CN101965188A CN 101965188 A CN101965188 A CN 101965188A CN 2009801075816 A CN2009801075816 A CN 2009801075816A CN 200980107581 A CN200980107581 A CN 200980107581A CN 101965188 A CN101965188 A CN 101965188A
Authority
CN
China
Prior art keywords
chemical compound
treatment
formula
patient
degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801075816A
Other languages
English (en)
Chinese (zh)
Inventor
托马斯·奥利吉诺
韩畅
蒂莫西·A·吉莱斯皮
拉马林加·达拉尼普拉加达
埃伦·马茨金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN101965188A publication Critical patent/CN101965188A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
CN2009801075816A 2008-03-10 2009-03-05 眼相关疾病的治疗 Pending CN101965188A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3507308P 2008-03-10 2008-03-10
US61/035,073 2008-03-10
PCT/US2009/036119 WO2009114373A1 (en) 2008-03-10 2009-03-05 Treatment for ocular-related disorders

Publications (1)

Publication Number Publication Date
CN101965188A true CN101965188A (zh) 2011-02-02

Family

ID=40583469

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801075816A Pending CN101965188A (zh) 2008-03-10 2009-03-05 眼相关疾病的治疗

Country Status (22)

Country Link
EP (1) EP2285378A1 (ko)
JP (1) JP2011513488A (ko)
KR (1) KR20110009084A (ko)
CN (1) CN101965188A (ko)
AR (1) AR070975A1 (ko)
AU (1) AU2009223501A1 (ko)
BR (1) BRPI0909659A2 (ko)
CA (1) CA2717991A1 (ko)
CL (1) CL2009000551A1 (ko)
CO (1) CO6290691A2 (ko)
CR (1) CR11644A (ko)
DO (1) DOP2010000266A (ko)
IL (1) IL207906A0 (ko)
MA (1) MA32211B1 (ko)
MX (1) MX2010008308A (ko)
NI (1) NI201000131A (ko)
NZ (1) NZ587906A (ko)
RU (1) RU2010141560A (ko)
SV (1) SV2010003658A (ko)
TW (1) TW200950784A (ko)
WO (1) WO2009114373A1 (ko)
ZA (1) ZA201005337B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005212B1 (ru) * 1999-12-24 2004-12-30 Авентис Фарма Лимитед Азаиндолы
AU778417B2 (en) * 2000-02-25 2004-12-02 Merck & Co., Inc. Tyrosine kinase inhibitors
KR20140025610A (ko) * 2005-09-30 2014-03-04 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.

Also Published As

Publication number Publication date
CR11644A (es) 2010-11-22
EP2285378A1 (en) 2011-02-23
SV2010003658A (es) 2011-01-31
BRPI0909659A2 (pt) 2015-09-22
KR20110009084A (ko) 2011-01-27
AU2009223501A1 (en) 2009-09-17
RU2010141560A (ru) 2012-04-20
JP2011513488A (ja) 2011-04-28
ZA201005337B (en) 2011-04-28
MA32211B1 (fr) 2011-04-01
AR070975A1 (es) 2010-05-19
CA2717991A1 (en) 2009-09-17
NI201000131A (es) 2011-09-29
CO6290691A2 (es) 2011-06-20
IL207906A0 (en) 2010-12-30
WO2009114373A1 (en) 2009-09-17
MX2010008308A (es) 2010-08-11
NZ587906A (en) 2011-12-22
TW200950784A (en) 2009-12-16
DOP2010000266A (es) 2010-09-30
CL2009000551A1 (es) 2009-08-21

Similar Documents

Publication Publication Date Title
KR20010005603A (ko) 인간면역결핍성 바이러스 및 그밖의 감염성 질환의 항미생물적 예방 및 치료
CN102711756A (zh) 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物
US10905671B2 (en) Method of using omega 3 fatty acids to treat diseases which involve damage to the nervous system
JP7089603B2 (ja) 眼疾患を治療するための脱メチル化
US7834056B2 (en) Pharmaceutical composition for gout
CN109381471A (zh) 包含柠檬苦素类化合物和双胍类化合物的组合产品
JP2022511371A (ja) Ｖａｐ－１の阻害剤
CN101123965B (zh) 哌甲酯衍生物及其应用
CN101965188A (zh) 眼相关疾病的治疗
EP2151237B1 (en) Pharmaceutical composition combining a non-steroidal anti-inflammatory agent and an anticonvulsant agent
JP2005531536A (ja) リパーゼ阻害薬及びグルコマンナンを含む医薬組成物
JP2021512921A (ja) 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
CN103391782A (zh) 用于预防或治疗伴有眼内血管新生及/或眼内血管渗透性过高的疾病的药物
HU230459B1 (hu) Makrolid alapú gyógyszerészeti készítmény szemészeti lokális alkalmazásra
CN101500567A (zh) P38激酶抑制剂治疗精神障碍的用途
CN101522185A (zh) 抗抑郁剂
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
JP2020504721A (ja) イブジラストを使用した多形膠芽腫の治療方法
WO2017106584A1 (en) Treatment of central nervous system and mental disorders with agonists of beta-3 adrenoceptor
CA2695822A1 (en) A combination treatment
JPH10147534A (ja) 腫瘍新生血管阻害物質及び医薬組成物
RU2020126396A (ru) Применение карримицина или его активных ингредиентов
US20110112101A1 (en) Treatment for ocular-related disorders
KR20220137542A (ko) 로베글리타존을 유효성분으로 하는 안과질환 치료용 조성물
WO2015165507A1 (en) Treatment of eye diseases using omega 3 fatty acids and aa/epa blood ratio

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1148691

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110202

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1148691

Country of ref document: HK